📰
Politics
Boehringer, Sino Enter Cancer Drug Deal Worth Over $7 Billion
📅4 November 2026 at 09:49
📰Bloomberg
👁️1 views
Share:
📰
Article Preview
Boehringer Ingelheim GmbH signed a licensing deal potentially worth more than $7 billion with China’s Sino Biopharmaceutical Limited and its subsidiaries for experimental cancer treatments.
🎧
Listen to Preview
Audio version available
🔇
Audio Reader
Not supported in this browser
Want the full story?
Click below to load the complete article with full details, analysis, and context.
Share this story
Share:
Source: This article was originally published by Bloomberg. All rights reserved to the original publisher.
Comments
Loading comments...
Related Stories
Stay Updated
Get the latest Nigerian news delivered to your inbox.